Want to see EDSA full AI Analyst Report?
EDSA Stock Chart & Stats
$1.48
>-$0.01(-0.02%)
At close: 4:00 PM EST
$1.48
>-$0.01(-0.02%)
Day’s Range― - ―
52-Week Range$0.72 - $20.32
Previous CloseN/A
Volume1.31K
Average Volume (3M)327.91K
Market Cap
$65.36M
Enterprise Value$51.17M
Total Cash (Recent Filing)$10.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.48
Next Earnings
Aug 07, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding8,891,951
10 Day Avg. Volume306,087
30 Day Avg. Volume327,910
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-496.89
Enterprise Value/Ebitda-4.88
Forecast
1Y Price Target
$21.00Price Target Upside1318.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.94
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA near-zero debt position and roughly $12.4M of equity materially reduce solvency and interest-rate risk, giving management financial flexibility to prioritize R&D and partnerships. This structural strength supports runway and optionality for clinical development over coming months.
Committed Insider-led FinancingAn insider-led PIPE that should generate about $3.5M provides committed near-term capital to advance the vitiligo and ARDS programs. Insider and sector specialist participation signals management alignment and increases probability of completing near-term development milestones without sole reliance on public market access.
Supportive Exploratory Clinical SignalsExploratory analyses indicating reduced mortality and improved kidney-specific outcomes for paridiprubart strengthen the scientific rationale for targeting TLR4-mediated inflammation. If replicable, these durable clinical signals can guide trial design, broaden indication potential, and de-risk aspects of the development program over the medium term.
Bears Say
Minimal Revenue And Deep LossesWith essentially no product revenue and roughly a $10.4M TTM net loss, the company lacks operating cash generation to fund growth. Persistently negative profitability limits strategic flexibility, increases dependence on external capital, and raises the risk that programs must be prioritized or scaled back if financing tightens.
Sustained Negative Cash FlowNegative operating cash flow near $7.6M TTM indicates ongoing cash burn tied to R&D and operations. Structural cash-generation weakness means recurring financings are likely; this constrains multi-program development, increases execution risk, and can force near-term trade-offs if capital markets become less accessible.
Expanded Equity Compensation / Dilution RiskShifting 90% of the CEO's salary into fully vested RSUs and expanding equity plan flexibility increases potential share issuance and lowers near-term cash burn. Structurally, this raises dilution risk for existing shareholders, complicates per-share economics and governance if future growth fails to offset increased equity-based compensation.
Edesa Biotech News
EDSA FAQ
What was Edesa Biotech’s price range in the past 12 months?
Edesa Biotech lowest stock price was $0.72 and its highest was $20.32 in the past 12 months.
What is Edesa Biotech’s market cap?
Edesa Biotech’s market cap is $65.36M.
When is Edesa Biotech’s upcoming earnings report date?
Edesa Biotech’s upcoming earnings report date is Aug 07, 2026 which is in 37 days.
How were Edesa Biotech’s earnings last quarter?
Edesa Biotech released its earnings results on May 14, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.26 by -$0.23.
Is Edesa Biotech overvalued?
According to Wall Street analysts Edesa Biotech’s price is currently Undervalued.
Does Edesa Biotech pay dividends?
Edesa Biotech does not currently pay dividends.
What is Edesa Biotech’s EPS estimate?
Edesa Biotech’s EPS estimate is -0.58.
How many shares outstanding does Edesa Biotech have?
Edesa Biotech has 8,891,951 shares outstanding.
What happened to Edesa Biotech’s price movement after its last earnings report?
Edesa Biotech reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.26. Following the earnings report the stock price went down -10.678%.
Which hedge fund is a major shareholder of Edesa Biotech?
Currently, no hedge funds are holding shares in EDSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edesa Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.00 (1318.92% Upside)
$21.00 (1318.92% Upside)
Blogger Sentiment
Bullish
EDSA Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 8.3%
Last 30 Days ▼ 8.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
300.49%
12-Months-Change
Fundamentals
Return on Equity
-82.34%
Trailing 12-Months
Asset Growth
-24.73%
Trailing 12-Months
Company Description
Edesa Biotech
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
EDSA Stock 12 Month Forecast
Average Price Target
$21.00
▲(1318.92% Upside)
Technical Analysis
Eterna Therapeutics
―
Lipocine
―
XTL Biopharmaceuticals Sponsored ADR
―
Cocrystal Pharma
―
BioVie
―
Ownership Overview
23.32% Insiders
1.41% Mutual Funds
24.25% Other Institutional Investors
50.11% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---